Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

uation

Unlike many of its biotech brethren, Unigene is not another developmental company with plenty of promise, but no sales. The Company not only has product sales, but based primarily on the strength of Fortical's sales, UGNE's most recent quarter (Q307) showed an operating profit. Going forward, we have modeled Fortical(R) sales to provide a slight net profit beginning in Q108, and continuing throughout the year.

We believe there are two very viable scenarios that could quickly elevate this company's success, and both are in the relatively short term. The first scenario occurs in the latter part of 2008 and involves the FDA's evaluation of reports of atrial fibrillation in bisphosphonate patients. After a series of serious side effects linked to long-term use of bisphosphonates, we believe this could be "the final straw" in tipping the risk/reward scale toward patients and physicians seeking osteoporosis therapies with proven safety profiles. The second scenario, which would have a huge impact on the sCT market, is FDA approval of oral calcitonin as a therapy for osteoarthritis. If clinical data is positive, we believe oral-sCT could become the first disease altering therapeutic available for the 21 million osteoarthritis sufferers in the U.S. We estimate this market launch could be as early as 2010. And notably, this launch could be followed by the launch of a Novartis oral calcitonin product. Both of these potential products are in Phase III trials.

Our model projects the majority of revenue to come from Fortical(R) sales over the next two years with 2007 revenue ending at slightly under $24 million, and an EPS of ($0.02). We have modeled 2008 revenue to total approximately $29.2 million, with an EPS of $0.01. We expect to see increased efficiencies in the manufacturing process over the next several quarters, adding to the bottom line as well. We have projected R&D to increase, but to remain relatively flat as a percentage of revenue. Gene
'/>"/>

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... WILMINGTON, Del. and CHARLOTTESVILLE, Va., Dec. 15 ... ) and the University of Virginia (UVa) ... entered into a strategic research collaboration to ... coronary artery disease (CAD) with a secondary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The ...
(Date:12/15/2009)... The International Society for Medical Publication Professionals (ISMPP) ... to accept abstracts for its 6th Annual Meeting, ... 19-21, 2010. This marks the first time that ... organization to submit an abstract to this increasingly ... EST, January 15, 2010. For submission details, please ...
(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...
(Date:12/14/2009)... Dec. 14 Array BioPharma Inc. (Nasdaq: ... ) today announced that they entered into an ... small-molecule glucokinase activator program, including ARRY-403, currently being ... patients with Type 2 diabetes. ,, ... receive an upfront payment of $60 million and ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7
... Test is Cepheid,s Second FDA Cleared Diagnostic Test in 2008; Test, ... ... Methods, SUNNYVALE, Calif., Oct. 1 Cepheid ... Drug,Administration (FDA) to market its Xpert(TM) MRSA/SA Blood Culture (BC),test, which runs ...
... Winners of 2008 R&D 100 Awards Now Online, ... the,finalists for the 8th Annual Innovator of the Year ... individuals who exemplify the,ideals of R&D in academia, industry, ... facilitated online with ten finalists,-- five scientists and five ...
... METTLER TOLEDO announces the launch of the FBRM® ... time. , ... ... 2008 -- Using probe-based FBRM (Focused Beam Reflectance ...
Other Biology Technology:Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 2Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 3Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 4Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures 52008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2Monitor Granule Growth in Process with the FBRM C35 2
(Date:12/16/2009)... Signal Hill, CA Tom Bowman, an expert ... of Bowman Global Change, has developed a series of ... Panel on Climate Change (IPCC) report for public audiences. ... scientific information they need to make informed decisions about ... new format as a means to clearly and accurately ...
(Date:12/16/2009)... YORK, Dec. 1 iQor, a global provider ... the 2009 InfoWorld 100 Awards Top 100 ... TeQ21. This was the first submission for iQor. ,, ... list of companies," said Vikas Kapoor, president and CEO ... do business, allowing us to work faster, smarter and ...
(Date:12/16/2009)... 2 DigitalPersona, Inc., a leader ... announced an agreement with IBM to deploy ... fingerprint technology on IBM SurePOS 500 retail ... point-of-sale applications to more easily and quickly ... be linked to the individuals who perform ...
Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Biomoda Board of Directors Names New Corporate Secretary 14614 1Biomoda Board of Directors Names New Corporate Secretary 14614 2TOPAZ Technologies Announces SoBran Inc as New Customer 14612 1TOPAZ Technologies Announces SoBran Inc as New Customer 14612 2TOPAZ Technologies Announces SoBran Inc as New Customer 14612 3CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 1CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 2CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 3CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 4CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 5
... people can approach animals in the wild more easily from ... innate "life detector" tuned to the visual movements of an ... , "We believe this visual filter is used to signal ... of their feet and the force of gravity," suggests Dr. ...
... journal Nature, scientists at the National Institute of Allergy ... Health (NIH) describe a new understanding about how long-term ... thinking about how to enhance certain immune responses and ... Germain, M.D., Ph.D., the scientists took videos through a ...
... a type of rodent-borne virus that can cause life-threatening ... rodent urine or droppings. , A team led ... Hughes Medical Institute (HHMI) international research scholar at the ... the new virus in an African wood mouse (Hylomiscus ...
Other Biology News:Animal brains 'hard-wired' to recognize predator's foot movements, Queen's study suggests 2Chemical guidance of T cells leads to immunologic memory and long-term immunity 2Chemical guidance of T cells leads to immunologic memory and long-term immunity 3Hantavirus found in African wood mouse 2Hantavirus found in African wood mouse 3Hantavirus found in African wood mouse 4
... An entire pressurized perfusion system for ... physiology, biophysics, electrochemistry, or general liquid-handling ... little as 100 microliters of precious ... solutions in milliseconds from a single ...
...
Request Info...
... a compact, highly versatile power supply. Capable of ... this power supply is ideal for PAGE, SDS-PAGE, ... all types of small format transfer apparatus. It ... constant current with a continuously variable output in ...
Biology Products: